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This consensus guideline was prepared on behalf of the International Society for Holter and Noninvasive Electrocardi-
ology and is cosponsored by the Japanese Circulation Society, the Computers in Cardiology Working Group on
e-Cardiology of the European Society of Cardiology, and the European Cardiac Arrhythmia Society. It discusses the
electrocardiographic phenomenon of T-wave alternans (TWA) (i.e., a beat-to-beat alternation in the morphology and
amplitude of the ST- segment or T-wave). This statement focuses on its physiological basis and measurement technol-
ogies and its clinical utility in stratifying risk for life-threatening ventricular arrhythmias. Signal processing techniques
including the frequency-domain Spectral Method and the time-domain Modified Moving Average method have dem-
onstrated the utility of TWA in arrhythmia risk stratification in prospective studies in 12,000 patients. The majority
of exercise-based studies using both methods have reported high relative risks for cardiovascular mortality and for
sudden cardiac death in patients with preserved as well as depressed left ventricular ejection fraction. Studies with
ambulatory electrocardiogram-based TWA analysis with Modified Moving Average method have yielded significant
predictive capacity. However, negative studies with the Spectral Method have also appeared, including 2 interven-
tional studies in patients with implantable defibrillators. Meta-analyses have been performed to gain insights into this
issue. Frontiers of TWA research include use in arrhythmia risk stratification of individuals with preserved ejection
fraction, improvements in predictivity with quantitative analysis, and utility in guiding medical as well as device-based
therapy. Overall, although TWA appears to be a useful marker of risk for arrhythmic and cardiovascular death, there is
as yet no definitive evidence that it can guide therapy. (J Am Coll Cardiol 2011;58:1309–24) © 2011 by the
American College of Cardiology Foundation
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T-Wave Alternans September 20, 2011:1309–24Physiology of TWA
The TWA phenomenon, a re-
peating ABABAB pattern in the
morphology and amplitude of the
ST-segment or T-wave, has long
been recognized and linked to ar-
rhythmogenesis (1). This pattern
distinguishes TWA from other
types of ST-segment and T-wave
variability (Fig. 1). TWA reflects
spatiotemporal heterogeneity of
repolarization, is sensitive to per-
turbations in intracellular calcium
handling, and serves as a mecha-
nism of arrhythmogenesis by amplifying repolarization heter-
ogeneity. It arises from beat-to-beat alternation of action
potential duration at the level of cardiac myocytes. TWA can
be either spatially concordant, when action potentials in neigh-
boring cell regions alternate in phase, or discordant, when they
are out of phase (Figs. 2 and 3) (2,3). The physiological basis
f TWA has recently been reviewed in detail (2–7).
ink to repolarization heterogeneity. The association of
WA with spatiotemporal heterogeneity of repolarization
i.e., transient or lasting repolarization differences among
eighboring myocardial regions) is supported by a number
f investigations, including in vitro optical mapping
2,3,5,7–9), intact large animal experimental laboratory
tudies (10–13), computer simulations, and clinical studies
nvolving programmed electrical stimulation (14,15).
igher levels of TWA indicate greater risk for arrhyth-
ias (13,16), which becomes especially elevated when
lternation in neighboring areas is discordant (i.e., out of
hase) (3,10). Changes in action potential duration and
onduction velocity restitution, premature beats, and
unctional and/or anatomic gradients in action poten-
ial duration facilitate development of steep, heteroge-
Figure 1 TWA and Nonalternating Fluctuations
(A) Precordial (V4) electrocardiogram rhythm strip (left) and high-resolution templa
coronary artery disease. The template illustrates T-wave alternans (TWA) as a sep
second. (B) Nonalternating fluctuations in T-wave amplitude after ajmaline adminis
Abbreviations
and Acronyms
CI  confidence interval
ECG  electrocardiogram
FFT  Fast Fourier
Transform
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MMA  Modified Moving
Average
TWA  T-wave alternanseous repolarization gradients conducive to re-entry and
avebreak.
nfluence of physiological interventions on TWA. TWA
agnitude coincides with vulnerability to lethal ventricular
achyarrhythmias. It is amplified by increased heart rates
16), ventricular premature beats (17), coronary artery oc-
lusion and reperfusion (5,12,14,18–20), adrenergic stimu-
ation (18,21), and mental stress (22). Blockade of beta-
drenergic receptors (23,24), sympathetic denervation (18),
nd vagus nerve and spinal cord stimulation (25), which
educe susceptibility to ventricular tachyarrhythmias, de-
rease TWA magnitude. Clinical studies with ambulatory
lectrocardiogram (ECG) monitoring (26) and recordings
rom intracardiac leads of implanted devices (27) reveal a
rogressive increase in TWA preceding the onset of spon-
aneous ventricular arrhythmias.
eart rate and autonomic factors. Heart rate influences
WA, likely by impacting on intracellular calcium cycling
4) and engaging the steepest portions of the electrical resti-
ution curve (7,28). Even in the normal heart, excessive heart
ates of170 beats/min in guinea pigs and200 beats/min in
anines are capable of inducing TWA (29). During myocardial
schemia or heart failure, the onset heart rate for TWA is
onsiderably lower (9,12) due to impaired capacity of the
arcoplasmic reticulum to reuptake calcium. Heart rate is not
he sole determinant of TWA, because autonomic neurotrans-
itters and changes in myocardial substrate can lead to
levated levels of TWA during fixed rate pacing (16,18).
urthermore, pacing alone does not replicate the TWA en-
ancement at comparable heart rates due to adrenergic stim-
lation or myocardial ischemia (21–24).
yocardial ischemia and heart failure. Myocardial isch-
mia can increase TWA magnitude, as was evidenced in
nimals during coronary artery occlusion (16,18,19) and in
umans during angioplasty (16,20). Experimental studies with
xed heart rates indicated that myocardial ischemia- and
RS-aligned complexes (right) during routine exercise testing from a patient with
between ST-T segments in A and B beats. TWA magnitude  106 V. Sec 
in a Brugada syndrome patient.te of Q
aration
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pi
s
r
s
a
i
c
T
a
a
w
m
s
t
r
s
s
d
o
t
v
l
1311JACC Vol. 58, No. 13, 2011 Verrier et al.
September 20, 2011:1309–24 T-Wave Alternansreperfusion-induced increases in TWA magnitude paralleled
(r2 0.98) incidence of ventricular tachycardia and fibrillation
(16). Marked changes in T-wave complexity and heterogeneity
(i.e., nonuniformity in T-wave morphology) (12,13) occurred
simultaneously with TWA magnitude surges, with transition
from concordant to discordant alternans. Loss of intercellular
coupling by ischemia was implicated when rotigaptide de-
creased connexin43 dephosphorylation in parallel with
ischemia-induced TWA and dispersion of repolarization (30).
Derangements in calcium cycling and conduction consti-
tute ionic bases for TWA during myocardial ischemia
and heart failure (8,9). With luminescent dyes, Clusin
(8) demonstrated ischemia-induced concordant and discor-
dant alternation in calcium transients. Moreover, calcium-
channel blockade reversed ischemia-induced TWA in par-
allel with arrhythmia suppression in anesthetized canines
(31). Experimental models of heart failure demonstrated
associations of TWA with disturbances in calcium handling
and development of discordant alternans, which set up
pro-arrhythmic preconditions for conduction block and
re-entry. In particular, heart failure reduced sarcoplasmic
reticulum calcium ion (Ca2)-adenosine triphosphatase ex-
ression and inhibited ryanodine receptor function, result-
Figure 3 Interlead Discordant Alternans
Mid-myocardial (Mid)/epicardial (Epi) recordings after an abrupt decrease in pacing
ture focal discharge from a left ventricular endocardial site, which induced areas o
calculated activation–recovery intervals (ARI). Numbers below the tracing are disp
ans is associated with the onset of ventricular tachyarrhythmia after a premature
Figure 2 Discordant Alternans Leading to VF
Action potential propagation between 2 ventricular sites (A to B) is shown with tra
tion (VF). Shaded areas indicate dispersion of repolarization between sites. *Prem
Adapted, with permission, from Oshodi et al. (2).ng in impaired reuptake and release of calcium in the
arcoplasmic reticulum, both contributing to marked de-
angements in intracellular Ca2 handling (9). Recent
tudies in cardiomyopathy patients showed that TWA may be
ttributable to oscillations in the action potential plateau that,
n computational models, were best explained by reduced
alcium uptake into the sarcoplasmic reticulum (15,28).
WA in nonischemic cardiomyopathy. Sympathetic nerve
ctivity and abnormalities in calcium handling may serve as
rrhythmogenic factors in nonischemic disease patients, in
hom enhanced adrenergic activity compensates for reduced
yocardial contractility. The vulnerable myocardial substrate is
usceptible to transient alterations in neural activity and elec-
rolyte imbalance, which may initiate disturbances in cardiac
epolarization and ventricular arrhythmogenesis. Imaging
tudies (32) demonstrated the important role of increased
ympathetic nerve activity in provoking TWA in idiopathic
ilated cardiomyopathy. During exercise, patients with dilated
r hypertrophic cardiomyopathy also experience repolariza-
ion abnormalities including TWA that are associated with
entricular tachycardia. Histopathological changes, particu-
arly fiber disarray and/or fibrosis, are correlated with TWA
length from 1,000 to 500 ms. Ventricular tachycardia was initiated by a prema-
tional conduction block and re-entrant excitation. Numbers above the tracing are
of ARI between mid-myocardial and epicardial sites. *Marked discordant altern-
eprinted, with permission, from Chinushi et al. (3).
n from concordant to discordant alternans and development of ventricular fibrilla-
beats. L  long action potential duration; S  short action potential duration.cycle
f func
ersion
beat. Rnsitio
ature
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T-Wave Alternans September 20, 2011:1309–24Clinical Studies With the Spectral Method Enrolling >100 PatientsTable 1 Clinical Studies With the Spectral Method Enrolling >100 Patients
First Author (Ref. #) Patient Population (Enrollment, Disease) Mean LVEF Hazard Ratios (95% CI) for TWA
Predictive studies
Cardiomyopathy
Kitamura et al. (34) 104 patients with DCM 37% 11.9 (1.53–92.59) for SCD, VF, or sustained VT at
21 14 months
Hohnloser et al. (35) 137 patients with DCM, LVEF 35% 29 11% 3.44 for ventricular tachyarrhythmic events at
14 6 months
Chow et al. (36) 514 patients with ischemic cardiomyopathy,
LVEF 35%, no previous sustained ventricular
arrhythmia and positive or indeterminate TWA
test results (patients included in Chow et al. [38])
26%–29% 2.24 (1.34–3.75) for all-cause mortality;
2.29 (1.00–5.24) for arrhythmic mortality;
NS for nonarrhythmic mortality
Salerno-Uriarte et al. (ALPHA) (37) 446 patients with DCM, LVEF 40% 29.5% 4.0 (1.4–11.4) for cardiac death and life-threatening
arrhythmias at 18 months
Chow et al. (38,39) 768 patients with ischemic cardiomyopathy,
LVEF 35%, no previous sustained ventricular
arrhythmia
26%–29% 2.27 (1.22–4.24) for all-cause mortality in patients
without an ICD; 2.42 (1.07–5.41) for all-cause
mortality or appropriate ICD discharge in patients
with an ICD. ICD use was associated with lower
all-cause mortality in MTWA non-negative patients
(0.45, 0.27–0.76) but not in MTWA negative
patients (0.85, 0.33–2.20), with mortality benefit
in MTWA-non-negative patients largely mediated
through arrhythmic mortality reduction (0.30,
0.13–0.68).
Chan et al. (40) 768 patients with ischemic cardiomyopathy,
LVEF 35%, no previous sustained ventricular
arrhythmia (same patients as Chow et al. [38])
26%–29% 2.19 (1.1–4.34) for all-cause mortality and
appropriate ICD shocks at 1 yr; 3.36 (1.28–8.83)
at 2 yrs
Costantini et al. (ABCD) (41) 566 patients with ischemic cardiomyopathy,
LVEF 40%, and NSVT
28 8% 2.1 for SCD or appropriate ICD discharge at 1 yr
Congenital heart disease
Alexander et al. (42) 304 consecutive pediatric patients with congenital
heart disease, myopathy, syncope, or history of
cardiac arrest
Not stated 7.9 (2.2–28.1) for ventricular arrhythmia; 6.7 (1.6–
28.1) for cardiac arrest at 3 yrs
Depressed LVEF
Rashba et al. (43) 108 consecutive patients with CAD and LVEF 40% 28 7% 2.2 (1.1–4.7) for death, sustained ventricular
arrhythmias, appropriate ICD discharge at
18 13 months in patients with normal QRS
segment; NS in patients with prolonged QRS
segment
Rashba et al. (44) 144 patients with CAD and LVEF 40% 28 7% 2.2 (1.1–4.7) for death, sustained ventricular
arrhythmia, or appropriate ICD discharge at
17 13 months; NS in patients with LVEF 30%;
 in patients with LVEF 30%
Bloomfield et al. (45) 549 patients with LVEF 40%, no history of
sustained ventricular arrhythmias
25% 6.5 (2.4–18.1) for all-cause mortality or nonfatal
sustained ventricular arrhythmia at 2 yrs
Cantillon et al. (46) 286 patients with LVEF 35%, NSVT or syncope 26 7% 2.33 (1.44–3.67) for arrhythmia-free survival at
38 11 months
Morin et al. (47) 386 patients with CAD, NSVT, LVEF 40% 26%–30% 1.64 for ventricular tachyarrhythmia or death in
patients with narrow QRS segment at 40 19
months; NS in patients with wide QRS segment
Heart failure
Klingenheben et al. (48) 107 consecutive patients with congestive heart
failure, LVEF 45%, no history of arrhythmia,
and no recent MI
28 7%  for SCD, arrhythmias, sustained VT at 14.6 months
Gorodeski et al. (49) 303 consecutive patients with heart failure and
LVEF 40%
24% 1.89 (1.05–3.39) for total mortality or cardiac
transplantation; NS after adjustment for metabolic
measures at 2.8 yrs. Concordance index for time-
to-event outcomes  0.75. C statistic for
propensity score  0.79.Continued on next page
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September 20, 2011:1309–24 T-Wave Alternansoccurrence and ventricular tachyarrhythmias in hypertrophic
cardiomyopathy (33).
Methodology for TWA Assessment
Two contemporary techniques employed in sizeable clinical
studies for arrhythmia risk stratification by microvolt-level
TWA are the Spectral and the Modified Moving Average
(MMA) Methods (Tables 1 and 2) (34–74). Both allow
etection of subtle levels of TWA in the nonvisible micro-
olt range as well as visible, macroscopic TWA. Experience
ith the Spectral Method is more extensive. Other analyt-
cal methods employed in experimental and clinical studies
18,20,26,75,76) have been reviewed (75).
pectral Method. ANALYSIS APPROACH. The concept of
analyzing morphology fluctuations in the T-wave by com-
ContinuedTable 1 Continued
First Author (Ref. #) Patient Population (Enrollment, Dis
Post-MI
Ikeda et al. (50) 102 post-MI patients
Ikeda et al. (51) 850 post-MI patients
Bloomfield et al. (52) 177 MADIT-II like post-MI patients with LV
Ikeda et al. (53) 1,041 post-MI patients with LVEF 40%
Exner et al. (REFINE) (54) 322 post-MI patients with LVEF 50%
Referred for electrophysiological study
Gold et al. (55) 313 patients
Rashba et al. (56) 251 patients with CAD and LVEF
Nonpredictive studies
Schwab et al. (57) 140 post-MI patients
Tapanainen et al. (58) 379 consecutive post-MI patients
Grimm et al. (59) 343 patients with DCM, LVEF 45%
Ikeda et al. (60) 124 consecutive subjects with Brugada-ty
Gold et al. (SCD-HeFT TWA substudy)
(61)
490 patients with congestive heart failure
Chow et al. (MASTER) (62) 575 post-MI patients with LVEF 30%
Huikuri et al. (CARISMA) (63) 312 post-MI patients
See text for discussion of nonsignificant prediction among studies with high or low implantable ca
time after myocardial infarction (MI). This table was developed from searches of the published m
Maryland) and Paperchase (Bedford, Massachusetts) databases. Reference lists from these studie
that enrolled over 100 patients and reported hazard ratios were included.
ABCD Alternans Before Cardioverter Defibrillator; ALPHA T-Wave Alternans in Patients With
CARISMA  Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction; CI  co
RT heart rate turbulence; ICD implantable cardioverter-defibrillator; LVEF left ventricular e
esting for Risk Stratification of Post-Myocardial Infarction Patients; NSVT nonsustained ventricular
haracteristic curve; SCD  sudden cardiac death; SCD-HeFT  Sudden Cardiac Death in Heart Failurputerized spectral techniques dates from experimental stud-ies (29) employing the Fast Fourier Transform (FFT) (Fig. 4)
(77). In detail, sequential ECG cycles are aligned to their QRS
complex, and the amplitude of the ST segments and T waves at
128 pre-defined points t (relative to the JT interval) is measured.
Subsequently, each beat-to-beat series of amplitude fluctuations is
processed with FFT to generate a separate spectrum for each point
t. The spectra corresponding to different time points along the JT
interval are averaged, producing a composite spectrum. The
voltage difference between the overall mean beat and the even- or
odd-numbered mean beats, or the alternans voltage in microvolts,
represents the square root of the alternans power at 0.5 cycle/beat.
The significance of TWA is expressed by the alternans ratio (K
score), calculated as the ratio of alternans power at 0.5 cycle/beat
divided by the standard deviation of spectral noise (78). The
greater the power, the higher is the alternans voltage. The ECG
Mean LVEF Hazard Ratios (95% CI) for TWA
20%–40% 16.8 (2.2–127.8) for arrhythmic events
51 13% 5.9 (1.6–21.4) for SCD or resuscitated VF at 25 13
months; 82% were monitored at 2–10 weeks
after MI
0 23 6% 4.8 for all-cause mortality at 2 yrs
55 10% 23.5 monitored at 48 66 days for SCD or life-
threatening arrhythmia at 32 14 months
40% within 1 week
and 47% at
8 weeks after MI
2.75 (1.08–7.02) monitored at 10–14 weeks after
MI for cardiovascular death or resuscitated
cardiac arrest (primary endpoint) at 47 months;
NS if monitored at 2–4 weeks after MI. AUC for
primary endpoint  0.62; for combination of
TWA  HRT, AUC  0.70.
44 18% 10.9 for SCD, sustained VT, VF, or appropriate ICD
discharge at 400 days
27 8% 2.2 (1.1–4.7) for arrhythmic events (arrhythmic
death, VT, aborted VF) at 499 395 days; NS for
TWA during atrial pacing at 100–120 beats/min
56 14% NS for TWA monitored at 15 6 days after MI for
SCD or sustained VT at 451 210 days
45 10% NS for TWA monitored at approximately 8 days after
MI for all-cause mortality or cardiac death at
14.8 months
31 10% NS for SCD, VF, or sustained VT at 52 months
(not stated) NS for SCD or VT at 40 19 months
24 7% NS for SCD, sustained VT/VF, or appropriate ICD
discharge at 2.5 yrs
24 5% 2.04 (1.10–3.78) for total mortality at 2.1 0.9 yrs;
NS for SCD or appropriate ICD discharge
31 6% NS for TWA monitored at 6 weeks after MI for VF or
symptomatic, sustained VT at 2 yrs
ter-defibrillator (ICD) use, continuance or withdrawal of beta-adrenergic blockade for test, or test
data on the terms alternans and alternation in PubMed (National Library of Medicine, Bethesda,
meta-analyses (88,112), and from recent reviews (4–7) were also scanned. Only clinical studies
ilure; AUC area under the receiver-operator characteristic curve; CAD coronary artery disease;
e interval; DCM  dilated cardiomyopathy; ECG  electrocardiogram; EP  electrophysiological;
fraction; MADITMulticenter Automatic Defibrillator Trial; MASTERMicrovolt T Wave Alternans
rdia; REFINE Risk Estimation Following Infarction, Noninvasive Evaluation; ROC receiver-operator
WA T-wave alternans; VF  ventricular fibrillation; VT ventricular tachycardia.ease)
EF 3
pe ECG
rdiover
edical
s, from
Heart Fa
nfidenc
jection
tachycafluctuations occurring at other frequencies are not included in
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T-Wave Alternans September 20, 2011:1309–24Clinical Studies With the Modified Moving Average MethodTable 2 Clinical Studies With the Modified Moving Average Method
Test Setting
First Author (Trial) (Ref. #)
Patient Population
(Enrollment, Disease, Mean Age) Mean LVEF
Hazard Ratios (95% CI) for TWA;
NPV and PPV
Routine exercise testing
Nieminen et al. (FINCAVAS) (64) 1,037 consecutive patients referred for
routine exercise testing; 58 13 yrs
(patients included in Leino et al. [66])
Mostly preserved 6.0 (2.8–12.8) for CV death, 7.4
(2.8–19.4) for SCD at 44 7 months
for 65-V TWA cutpoint; NPV for CV
death  97.6; PPV  12.6; NPV for
SCD  98.6, PPV  8.0
Minkkinen et al. (FINCAVAS) (65) 2,119 consecutive patients referred for
routine exercise testing; 57 13 yrs
(patients included in Leino et al. [66])
Mostly preserved 4.6 (2.2–9.9) for CV death, 4.4
(1.5–12.7) for SCD at 47 months
for 65-V cutpoint; NPV for CV
death  97.4; PPV  10.2
Leino et al. (FINCAVAS) (66) 3,598 consecutive patients referred for
routine exercise testing; 56 13 yrs
Mostly preserved 1.55 (1.150–2.108, p  0.004) for CV
death; 1.58 (1.041–2.412; p 
0.033) for SCD at 55 months per
20 V TWA in lead V5.
Exercise recovery
Exner et al. (REFINE) (54) 322 post-MI patients; 62 (interquartile range:
53–70) yrs
Moderately depressed (38%–48%) 2.94 (1.10–7.87) monitored at 10–14
weeks after event for CV death or
resuscitated cardiac arrest (primary
endpoint) at 47 months; NS when
monitored at 2–4 weeks after MI.
For primary endpoint for TWA,
AUC  0.62; for combination of
TWA  HRT, AUC  0.71.
Slawnych et al.
(REFINE/FINCAVAS) (67)
322 post-MI patients (from REFINE) and
681 CAD patients (from FINCAVAS);
69 (interquartile range: 57–76) yrs
Moderately depressed (38%–48%) and
preserved (56%–63%) groups
2.5 (1.1–6.0) for CV death at 48
months for 60-V cutpoint;
NPV  96%; PPV 13%. AUC for
CV mortality  0.69.
Leino et al. (FINCAVAS) (68) 1,972 consecutive patients referred for
routine exercise testing; 57 13 yrs
(patients included in Leino et al. [66])
Mostly preserved 3.5 (1.6–7.9) for CV death at 48
months for 60-V cutpoint. For CV
death for TWA alone, C-statistic 
0.550–0.606; for combination of
TWA  HRR, C-statistic  0.671–
0.691.
Ambulatory ECG monitoring
Verrier et al. (ATRAMI) (69) Acute post-MI; case: control analysis
(15 cases: 29 control subjects) from
1,284 ATRAMI patients, monitored at
15 10 days post-MI; 60–62 yrs
Moderately depressed (42 3%) 7.9 (1.9–33.1) for cardiac arrest or
arrhythmic death at 21 months for
a priori 75th percentile cutpoint
(47 V); patients were monitored
at 15 10 days post-MI
Stein et al. (EPHESUS) (70) Acute post-MI, LVEF 40%, and heart failure;
case: control analysis (46 cases:
92 control subjects) from 6,632 EPHESUS
patients, monitored at 2–10 days post-MI;
68 11 yrs
Depressed (34 5%) 5.5 (2.2–13.8) for SCD at 16.4
months for 47-V cutpoint; patients
were monitored at 2–10 days post-
MI. For SCD, AUC  0.73 for TWA
in lead V1 and  0.70 in lead V3
(p  0.001).
Sakaki et al. (71) 295 consecutive cardiomyopathy patients
with ischemic or nonischemic left
ventricular dysfunction; 66 16 yrs
Depressed (34 6%) 17.1 (6.3–46.6) for CV death,
22.6 (2.6–193.7) for witnessed SCD
at 1 yr for 65-V cutpoint; NPV for
CV death  97%; PPV  37%
Maeda et al. (72) 63 consecutive patients including 21 control
subjects, 21 post-MI patients without VT,
and 21 post-MI patients with VT;
65 11 yrs
Depressed (36%–43%) for post-MI group 6.1 (1.1–34.0) for sustained VT or VF
at 6 yrs for 65-V cutpoint
Stein et al. (CHS) (73) General population patients age 65 yrs;
case: control analysis (49 cases:
98 control subjects) from 1,649 CHS
patients
Not tested, assumed preserved 4.8 (1.48–15.81) for SCD at 14 yrs
Hou et al. (74) 219 consecutive acute post-MI patients;
55 yrs
35% in 201; 35% in 18 17.78 (3.75-84.31) for SCD within
16 months for 47-V cutpoint;
patients were monitored at 1–15
days post-MI; NPV  99%; PPV 
17%
This table is based on searches of the published medical data on the terms alternans and alternation for all clinical studies that reported hazard ratios in PubMed (National Library of Medicine, National
Institutes of Health, Bethesda Maryland) and Paperchase (Bedford Massachusetts) databases. Reference lists from these studies and from recent reviews (4–7) were also scanned.ATRAMI  Autonomic Tone and Reflexes after Myocardial Infarction; CHS  Cardiovascular Health Study; CV  cardiovascular; EPHESUS  Eplerenone Post-Acute Myocardial Infarction Heart Failure
Efficacy and Survival Study; FINCAVAS  Finnish Cardiovascular Study; HRR  heart rate recovery; NPV  negative predictive value; PPV  positive predictive value; other abbreviations as in Table 1.
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September 20, 2011:1309–24 T-Wave AlternansTWA assessment. Use of this technique in clinical practice is
evidenced by substantial sales of commercial equipment and
consumables as publicly reported by Cambridge Heart, Inc.
TEST METHODOLOGY. Because the Spectral Method involves a
raded increase in heart rate, the TWA test is usually conducted
uring bicycle or treadmill exercise to an optimum heart rate (79).
ome investigators infused chronotropic agents (21,24) or em-
loyed atrial pacing to elevate and stabilize heart rate (23,56,80–
2). TWA can occur in normal individuals at heart rates 120
eats/min. Consequently, a target heart rate range of 105 to 110
eats/min was determined for pathologic alternans in adults
78,82). Practice has varied with regard to withholding beta-
drenergic blockade to allow patients to reach this heart rate (83).
he current recommendation is to maintain chronic medications
uring the test (23).
TWA is determined from standard precordial and orthogonal
,Y,Z leads. Special high-resolution electrodes can minimize
oise. TWA is not measured in ECG portions in which ectopic
r premature beats constitute 10% of beats (78), because the
eadings can be influenced by excessive numbers of premature
eats or by attendant phase changes of alternans (e.g., from
ABAB” to “BABA”).
CLASSIFICATION OF TEST RESULTS. TWA level 1.9-V
utpoint with alternans signal-to-noise ratio K3 sustained
Figure 4 Spectral TWA Method
Schematic representation of T-wave alternans (TWA) assessment of the electrocar
FFT  Fast Fourier Transform.or 2 min is defined as a positive test result on the basis ofutcome data of clinical studies (55,78). Test results below
his level are considered negative.
Because of a relatively high incidence (20% to 40% of all
ases) of indeterminate test results, a test classification of
abnormal due to patient factors” was introduced (84). This
lassification is employed when the test is associated with
xcessive ectopy (approximately 32%), lack of capacity to
each a target rate of 105 to 110 beats/min (approximately
1%), or nonsustained TWA (approximately 10%). Abnor-
al test results due to patient factors carry greater risk than
ositive test results. In contrast, the occurrence of muscle,
espiration, or other movement artifacts or electrode noise
ccounts for 6.4% of indeterminate test results in experi-
nced centers and is referred to as “technically indetermi-
ate.” Those tests have no prognostic value per se.
MA method. ANALYSIS APPROACH. The MMA method
employs the noise-rejection principle of recursive averaging
(75). The algorithm continuously streams odd and even
beats into separate bins and creates median complexes for
each bin (Fig. 5) (19). These complexes are then superim-
posed, and the maximum difference between the odd and
even median complexes at any point within the JT segment
is averaged for every 10 to 15 s and reported as the TWA
value. The moving average allows control of the influence of
new incoming beats on the median templates with an
m (ECG) with the Spectral Method (77). See text for details.diograadjustable update factor (i.e., the fraction of morphology
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T-Wave Alternans September 20, 2011:1309–24change that an incoming beat can contribute). The recom-
mended rapid update factor of one-eighth provides greater
sensitivity and capacity to detect transient but clinically
important surges in TWA than one-sixteenth or one-thirty-
second (64). Noise measurements are in part derived from
mismatch of the even or odd median complexes outside the
JT segment. The algorithm excludes extrasystoles, noisy
beats, and the beats preceding them and filters effects of
noise, movement, and respiration.
TEST METHODOLOGY. The MMA allows microvolt TWA
analysis during routine, symptom-limited exercise stress
testing (64 – 66,68) and during post-exercise recovery
(54,67,68) as well as during ambulatory ECG monitoring
(69–74) in the flow of clinical evaluation (Table 2). Risk
stratification is based on the peak TWA value throughout
the 24-h ambulatory ECG recording or the symptom-
limited exercise test.
MMA-based TWA is calculated from standard precor-
dial ECG leads with standard electrodes (64–74). Because
limb leads are prone to motion artifact (65), TWA in these
Figure 5 MMA TWA Method
Flow chart of the major components of the Modified Moving Average (MMA)
method of T-wave alternans (TWA) analysis. See text for details.
Adapted, with permission, from Nearing et al. (19).leads should be interpreted with caution. The MMAmethod generates high-resolution templates of superim-
posed QRS-aligned complexes showing the alternation
pattern, which permit visual examination to verify the
presence and magnitude of TWA (Fig. 1) (65,70). TWA
values should be over-read for verification down to 20 V.
CLASSIFICATION OF TEST RESULTS. MMA-based TWA
studies with ambulatory ECG recordings and exercise
support the concept that TWA represents a continuum
of risk with higher TWA levels indicating greater risk
(64–68). With the recommended update factor of one-
eighth, TWA 60 V during routine exercise testing
64–68) and ambulatory ECG monitoring (69–74) indi-
ates severely elevated risk for sudden cardiac death and/or
ardiovascular mortality. In patients during the early
ost-MI phase with or without heart failure, a cutpoint of
47 V also predicted sudden cardiac death (69,70,74).
eino et al. (66) demonstrated a 55% and 58% increase in
isk of cardiovascular and sudden cardiac death, respectively,
er 20 V of TWA.
Short- and long-term repeatability of TWA testing. Im-
mediate repeatability of the Spectral Method test results was
verified with bicycle ergometry with 15 min and 4 h
between the tests (85) as well as during atrial pacing (24).
Data on long-term stability of TWA results with the
Spectral Method are sparse (86). Repeatability has not been
reported with the MMA method.
Comparison of TWA values obtained with the Spectral
and MMA methods. The methods are analytically com-
parable, although they differ in noise processing. The 4- to
10-fold differences in TWA voltages reported by MMA and
Spectral Method tests can be accounted for by the update
factor (87). Also, the Spectral Method reports one-half of
the average TWA magnitude across the entire JT interval
for 128 beats, whereas the MMA method reports the peak
TWA level at any point within the JT interval for each 10-
to 15-s interval.
Clinical Utility
Spectral Method. Significant predictivity of TWA analysis
by the Spectral Method has been prospectively demon-
strated in 7,200 patients with various types of cardiovas-
cular disease, including myocardial infarction, congestive
heart failure, ischemic cardiomyopathy, and nonischemic
dilated cardiomyopathy (Table 1) (Figs. 6A and 6B)
(37,54). Lack of significant predictivity in a few observa-
tional studies has been attributed to short periods after
myocardial infarction during ongoing remodeling (57,58),
washout of beta-blocking agents before the test (23,59,83),
and use of implantable cardioverter-defibrillator (ICD)
firing as a surrogate endpoint for arrhythmic death
(61,62,88).
A focus of most TWA studies with the Spectral Method
has been on identifying patients who would not benefit from
ICD implantation, particularly those fulfilling the MADIT
II (Multicenter Automatic Defibrillator Trial II) criteria,
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September 20, 2011:1309–24 T-Wave Alternansnamely, prior myocardial infarction and left ventricular
ejection fraction (LVEF) 30% (52,62). The need for
accurate identification of patients who would not benefit
from ICD implantation is underscored by the facts that
one-third of ICD patients receives an inappropriate shock
within 1 to 3 years of implantation (89,90), and ICD shock
is associated with a 2- to 5-fold increase in mortality, most
commonly due to progressive heart failure (90). Event-free
survival from all-cause or cardiac mortality and/or ventric-
ular tachyarrhythmias averaged 97% to 98% in patients with
negative TWA test results, pointing to a potential to
improve exclusion of patients who may not benefit from
primary prophylactic ICD implantation, despite meeting
evidence-based criterion of LVEF 35% (52,91).
TWA IN INTERVENTIONAL ICD TRIALS. TWA stratified to-
al mortality in the MASTER (Microvolt T Wave Altern-
ns Testing for Risk Stratification of Post-Myocardial
nfarction Patients) trial of MADIT II-type patients but
Figure 6 Survival Curves for Prospective TWA Studies
(A) The ALPHA (T-Wave Alternans in Patients with Heart Failure) T-wave alternans (
mias) survival according to TWA Spectral Method testing (37). Patients at risk are
Noninvasive Evaluation) TWA study (54). Risk of cardiac death or resuscitated card
with heart rate turbulence  abnormal repolarization alternans  ejection fraction
Method during exercise; right panel indicates results of MMA analysis during reco
study of SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) (61). Comparison
line) and negative (solid line) patients (n  490). No significant difference betwee
(61). (D) Ambulatory electrocardiogram (ECG) TWA study (71). Event-free survival f
basis of maximum TWA voltage by the Modified Moving Average (MMA) method. Cid not predict sudden cardiac death or appropriate ICDischarge in the MASTER trial (62) or sudden cardiac
eath, sustained ventricular tachycardia or fibrillation, or
ppropriate ICD discharge in the SCD-HeFT (Sudden Car-
iac Death in Heart Failure Trial) TWA substudy (Fig. 6C)
61). A recent meta-analysis addressing lack of predictivity
f ICD discharge in these trials indicated that predictive
ccuracy was strong in the TWA studies enrolling relatively
ew patients with ICDs, with a composite hazard ratio for
rediction by abnormal versus negative TWA of 13.6 (95%
onfidence interval [CI]: 8.5 to 30.4) and that predictive
ccuracy in studies with high ICD use was low at 1.6 (95%
I: 1.2 to 2.1) (88). Thus, ICD firing, employed as a
urrogate endpoint for sudden cardiac death, may have
nderrepresented the utility of the test. An alternative
xplanation implicates withholding beta-adrenergic block-
ng agents to explain the inconsistent results (Fig. 7) (83).
GUIDING ICD IMPLANTATION. Data to support use of
TWA to withhold or delay ICD implantation are insuffi-
study: Kaplan-Meier cumulative event-free (cardiac death/life-threatening arrhyth-
at selected time points. (B) The REFINE (Risk Estimation Following Infarction,
rest (primary outcome) among patients with impaired autonomic tone, measured
versus remaining patients. Left panel indicates TWA results with the Spectral
om exercise. Patients at risk are shown at selected time points. (C) TWA sub-
ary event rates for microvolt T-wave alternans (MTWA) in non-negative (dashed
nt rates was found for the 2 groups. Reprinted, with permission, from Gold et al.
rdiac mortality in ischemic (left) and nonischemic (right) subgroups on the
nfidence interval.TWA)
shown
iac ar
50%
very fr
of prim
n eve
rom ca
I  cocient at present. To date, only the ABCD (Alternans Before
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T-Wave Alternans September 20, 2011:1309–24Cardioverter Defibrillator) trial (41) has tested the capacity
of TWA to guide prophylactic ICD implantation. Event
rates were higher in patients with either a positive TWA
(hazard ratio: 2.1, p  0.03) or a positive electrophysiolog-
cal study (hazard ratio: 2.4, p 0.007) than in those whose
TWA and electrophysiological tests were either negative or
indeterminate at the pre-specified primary time point of 1
year. Moreover, the event rate in patients with both negative
TWA and electrophysiological study test results was lower
than in patients with 2 positive tests (2% vs. 12%; p 
0.017), suggesting synergy between the tests. But, TWA did
not predict endpoint events at 2 years, suggesting potential
time dependence.
In their meta-analysis, Hohnloser et al. (88) proposed a
clinical algorithm to identify patients who would not benefit
from ICD implantation for primary prevention. (See their
Fig. 2.) Their analysis revealed that the mortality rate of
TWA negative patients with LVEF35% but no history of
ventricular arrhythmias and no prior ICD implantation was
4-fold lower than that of MADIT II or SCD-HeFT trial
patients randomized to ICD therapy. Accordingly, the
negative predictive value derived for this group is 99%.
Figure 7 Beta-Blocker TWA Meta-Analysis
Association between microvolt TWA analyzed by the Spectral Method and ventricul
therapy. Washout of beta-adrenergic blockade impaired predictivity. Risk ratio (RR)
mates for meta-analysis were hazard or risk ratios. **No events in microvolt TWA
Table 1. Reprinted, with permission, from Chan et al. (83).This algorithm will require testing in a prospective trial.TWA IN HEREDITARY CHANNELOPATHIES. Although intra-
cardiac repolarization alternans plays a pivotal pathogenetic
role in the genesis of malignant arrhythmias, particularly
torsades de pointes, in channelopathies (92), prospective
studies have not demonstrated that TWA analysis by the
Spectral Method identifies patients with long QT (93,94)
or Brugada syndromes (60,95) who will experience epi-
sodes of torsades de pointes. The disappearance of TWA
during atrial pacing at 110 beats/min provides clues with
regard to difficulties in sensing TWA during target heart-rate
exercise in Brugada patients (96).
MMA method. Predictivity of TWA analysis by the
MMA method has been demonstrated in 4,800 patients,
including those with coronary artery disease, recent or old
myocardial infarction, congestive heart failure, or cardiomy-
opathy (Table 2). In FINCAVAS (Finnish Cardiovascular
Study), the largest investigation of TWA to date, TWA
predicted sudden cardiac death and cardiovascular and
total mortality in a general population of 3,500 low-risk
patients referred for routine, symptom-limited exercise
testing (64 – 66,68). MMA-based TWA is also predictive
when monitored during immediate post-exercise recovery
ythmic events, stratified by screening protocol discontinuation of beta-blocker
4 reflects 0.5 correction factor; therefore, no 95% CI is depicted. *Study esti-
ve group (p  0.04). ***Test for heterogeneity: p  0.025. Abbreviations as inar arrh
: 12.4
negati(54,67,68) or from ambulatory ECG records (69 –74)
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September 20, 2011:1309–24 T-Wave Alternans(Fig. 6D). Sudden cardiac death was witnessed (71) or
judged by physician review (68,73,97) or an events
committee (98,99). TWA detected with continuous 24-h
ECG monitoring reflects the influences of daily activity,
mental stress (22), sleep states (100), and sleep apnea
(101). Results of these investigations support MMA
analysis of TWA during the flow of routine clinical
assessment.
Comparison of the predictivity of TWA with the Spectral
and MMA methods. Hazard ratios for prediction by the
Spectral and MMA methods are similar, whether in the
same population (54) or in studies overall (Tables 1 and 2).
xner et al. (54) determined that TWA assessed by the
pectral Method during exercise and by the MMA method
uring the post-exercise recovery phase yielded significant
dds ratios of 2.75 and 2.94, respectively, in 322 post-
yocardial infarction patients with better-preserved LVEF
mean 47% measured at 8 weeks after myocardial infarction)
ut without an ICD who were enrolled in the REFINE
Risk Estimation Following Infarction, Noninvasive Eval-
ation) study (Fig. 6B). The concordance of the 2 methods
easured simultaneously during exercise has not been
ystematically investigated. In a study using atrial pacing
n  41), Cox et al. (80) found that the Spectral Method
as predictive (p  0.02) and that, with their customized
oftware and with one-sixteenth rather than the recom-
ended one-eighth update factor, MMA was nearly signif-
cant (p  0.06) in the same patients. TWA analyzed by
oth the Spectral Method and MMA was significantly
levated at 8 to 15 min before the onset of spontaneous
entricular tachyarrhythmias in ambulatory ECGs in the
SVEM (Electrophysiologic Study Versus Electrocardio-
raphic Monitoring) trial (26).
isk stratification in patients with preserved ejection
raction. An important frontier in arrhythmia risk stratifi-
ation concerns patients with preserved LVEF, in whom the
ajority of sudden cardiac deaths occur albeit with low
ncidence (102). Ikeda et al. (53) with the Spectral Method
nd the FINCAVAS investigators (64–68) with the MMA
ethod showed that TWA can identify individuals with
reserved LVEF but heightened risk for sudden cardiac
eath. Positive predictivity in this population is relatively
ow, in the 8% to 10% range, typical for prognostic markers
pplied to low-risk groups.
ombinations of noninvasive parameters to improve risk
tratification. Improved risk stratification in patients with
reserved LVEF can be attained by a combination of
oninvasive markers, because the capacity to detect risk
ncreases markedly when more than 1 factor is analyzed
103). Hazard ratios increased by 30% to 212% (54,68) and
ositive predictive value by 78% (50) when cardiac electrical
nstability quantified by TWA was combined with signal-
veraged ECG, heart rate turbulence, or heart rate recovery,
hich are independent markers of risk of cardiovascular
eath and may disclose the mechanistic basis for TWA. Use
f combinations of noninvasive parameters, specifically in-luding TWA, was recently recommended in a National
eart, Lung, and Blood Institute and Heart Rhythm
ociety Workshop report on sudden cardiac death predic-
ion and prevention (104), citing complexities of myocardial
ubstrates underlying sudden cardiac death risk. However,
igh levels of TWA even in the absence of additional risk
arkers should be noted.
uantitative analysis of TWA voltage. GRADED ASSESSMENT
F RISK. To date, most TWA studies have employed a
binary approach to classify test results as either negative or
abnormal on the basis of a cutpoint. However, because
TWA reflects a continuum of cardiac electrical instability,
its quantification offers the potential for diagnosing levels of
risk and for improving prognostics. Treating a continuous
variable as binary reduces predictive power by one-third to
one-half (105).
Clinical studies using either the Spectral (26,106) or
MMA methods (26,64–68) reveal that higher TWA mag-
nitudes indicate increased risk for ventricular tachyarrhyth-
mias. Klingenheben et al. (106) found in patients with
infarct-related or nonischemic cardiomyopathy that TWA
magnitude and not merely its presence was associated with
tachyarrhythmic complications. In the FINCAVAS data-
base, Minkkinen et al. (65), Slawnych et al. (67), and Leino
et al. (66) reported that sudden cardiac death incidence and
cardiovascular and total mortality rose with elevated TWA
values (Fig. 8) (67). Leino et al. (66) determined that risk
for cardiovascular death and sudden cardiac death increased
by 55% and 58%, respectively, for each 20 V of TWA. A
crescendo in TWA magnitude consistently occurred before
onset of life-threatening ventricular tachyarrhythmias in
ambulatory subjects with ischemic heart disease enrolled in
the ESVEM (Electrophysiologic Study Versus Electrocar-
diographic Monitoring) trial (26). During the arrhythmia-
free period, TWA was significantly lower than during the
Figure 8 The REFINE/FINCAVAS TWA Study
Rates of cardiovascular death (orange bars) and total mortality (blue bars) at
4 years, by quintile of TWA magnitude with the MMA method (67). FINCAVAS 
Finnish Cardiovascular Study; other abbreviations as in Figure 6.
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T-Wave Alternans September 20, 2011:1309–2415 min immediately preceding ventricular tachycardia onset.
Quantitative TWA analysis may allow tracking changes
in risk over time, as patients recover and the myocardium
remodels, as cardiac disease or heart failure status are
altered, or in response to medical therapy. TWA quantifi-
cation also permits comparison of risk levels across different
populations and disease states. For example, it was recently
shown that TWA is markedly elevated (60 V) in dialysis
atients in the absence of an acute cardiovascular event,
onsistent with their established heightened risk for sudden
ardiac death (107).
GUIDING MEDICAL THERAPY. Clinical studies and reports
uggest that the magnitude of TWA reflects the effects of
harmacologic therapy without reducing the predictive capac-
ty of the phenomenon (108). Beta-adrenergic (23,24,83)
nd sodium channel blocking agents (109) diminish TWA
agnitude, reflecting the capacity of these agents to reduce
udden cardiac death and cardiovascular mortality (110). In
he Brugada syndrome, sodium channel blockade provokes
he diagnostic ECG changes as well as macroscopic TWA
nd arrhythmias (111). The proarrhythmic effects associated
ith cardiovascular and noncardiovascular agents are also
isclosed by elevated levels of TWA.
Because antiadrenergic and antiarrhythmic drugs influence
WA, the decision to withhold these agents at the time of
WA testing is a matter of debate. Some investigators with-
eld beta-blocker therapy to avoid drug-induced chronotropic
ncompetence (36,38,39,41,61,62), whereas others performed
he test with full cardioprotective medication (35,37,45,48). In
meta-analysis, Chan et al. (83) determined that the predictive
apacity of TWA for ventricular arrhythmic events was signif-
cantly weaker in studies withholding beta-blockade therapy
relative risk: 1.40; 95% CI: 1.06 to 1.84; p  0.02) than in
studies performed with discharge medications (relative risk:
5.39; 95% CI: 2.68 to 10.84; p 0.001) (Fig. 7). An important
corollary of these findings is that the effects of medications on
TWA represents not a disruption in measurement but an
indication of therapeutic efficacy (108).
Summary and Recommendations
for Clinical Practice
An extensive body of evidence from prospective studies in
12,000 patients with depressed or preserved LVEF sup-
ports the use of TWA analysis in assessing risk for cardio-
vascular mortality and sudden cardiac death (Tables 1 and 2)
(112). Hazard ratios generated by the Spectral and MMA
methods are similar, whether in the same population (54) or
in studies overall. Multivariate analyses confirm that TWA
provides information on risk beyond standard clinical vari-
ables for cardiovascular disease, including demographic
factors (e.g., age, sex, and race) and traditional cardiovas-
cular risk markers (e.g., smoking, blood pressure, history,
and medications). Currently, the only established risk
marker for sudden cardiac death and the only parameter
approved to identify high-risk patients for ICD implanta-tion is depressed LVEF (113). This parameter has signifi-
cant limitations, as underscored by the fact that the majority
of individuals who die suddenly have preserved LVEF
(102). TWA is being assessed along with candidate genes as
arrhythmia markers in a large cohort of patients with ICDs
for ICD shock risk and mortality in EUTrigTreat (EU
TrigTreat Clinical Study: An Arrhythmia Risk Stratification
and Genetic Trial) (Clinical trials identifier: NCT01209494)
and in the GAME (Medtronic Genetic Arrhythmia Mark-
ers for Early Detection) study (Clinical trials identifier:
NCT00664807).
Accordingly, we concur with the recommendations of
guidelines committees of the American Heart Association,
American College of Cardiology, European Society of
Cardiology, and/or Heart Rhythm Society chaired by Zipes
et al. (114), who assigned Class I Level of Evidence: A and
Class IIa Level of Evidence: A indications to TWA testing
for arrhythmia risk, and led by Goldberger et al. (115), who
determined that TWA provides valuable information with
regard to risk for cardiovascular mortality and sudden
cardiac death. Additional applications recommended by task
force or consensus statement authors are in neonates, in
whom the appearance of TWA signals the highest level of
risk (116), and in hospital settings to warn of the develop-
ment of torsade de pointes (117).
Interventional trials, which have been performed to date
only with the Spectral Method, have not demonstrated that
a negative TWA test result can sufficiently guide decision-
making with regard to ICD implantation (41,61,62). Thus,
TWA should not be used as a sole parameter either to rule
in or to rule out ICD use. A clinical algorithm that
incorporates LVEF in the decision-making process appears
promising on the basis of a meta-analysis (88). However,
this proposal will require prospective testing. Also, use of
more advanced statistical approaches and criteria for evalu-
ation of novel markers of cardiovascular risk is recom-
mended (118).
Acknowledging the complexities of myocardial substrates
underlying sudden cardiac death risk, a recent National
Heart, Lung, and Blood Institute and Heart Rhythm
Society Workshop report on prediction and prevention
proposed combinations of risk markers specifically including
TWA (104). The utility of ambulatory TWA combined
with heart rate turbulence, an indicator of baroreceptor
sensitivity (119), to identify post-myocardial infarction pa-
tients with preserved LVEF who would benefit from ICD
implantation is the subject of an ongoing clinical trial,
REFINE-ICD (Risk Estimation Following Infarction,
Noninvasive Evaluation of ICD Therapy) (120) (Clinical
trials identifier: NCT00673842).
The time period for optimum predictive accuracy of
TWA for arrhythmic events, cardiovascular mortality, and
total mortality in patients with acute myocardial infarction
is under investigation in a clinical trial, T-Wave Alternans
in Acute Myocardial Infarction: An Evaluation of the Time
of Testing on Its Prognostic Accuracy (Clinical trials
1321JACC Vol. 58, No. 13, 2011 Verrier et al.
September 20, 2011:1309–24 T-Wave Alternansidentifier: NCT00589849). Exner et al. (54) determined
that, for long-term prediction, TWA testing should be
performed at 10 to 14 weeks after myocardial infarction,
while others (69,70,74) found significant risk stratification
with TWA monitoring at 15 days post-MI. There is a
rationale for considering earlier TWA testing, because 1.4%
of patients (approximately 17,500 in the United States)
experience sudden cardiac death in the first month after
myocardial infarction during the acute remodeling period
(121).
Evidence supports the value of quantitative TWA anal-
ysis for both the Spectral and MMA methods. Quantifica-
tion offers inherent advantages with respect to gauging level
of risk across time after cardiovascular events and in evalu-
ation of the potential anti- and pro-arrhythmic effects of
medical therapy by conventional and nonconventional
agents (108). These applications merit exploration in inter-
ventional trials.
It is recommended that TWA testing be performed on
discharge medications, particularly with respect to beta-
blockade therapy (23,83), to ensure that the test results
reflect the effects of chronic drug therapy.
Conclusions
Overall, our assessment is that it is reasonable to consider
TWA evaluation whenever there is suspicion of vulnerabil-
ity to lethal cardiac arrhythmias. However, there is as yet no
definitive evidence from interventional trials that it can
guide therapy.
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